diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.
Pre-clinicalCompleted 0 watching 0 views this week๐ค Quiet
23
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Dry Eye
Conditions
Dry Eye
Trial Timeline
Feb 1, 2010 โ Apr 1, 2012
NCT ID
NCT01101984About diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution.
diquafosol ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solution. is a pre-clinical stage product being developed by Santen Pharmaceutical for Dry Eye. The current trial status is completed. This product is registered under clinical trial identifier NCT01101984. Target conditions include Dry Eye.
Hype Score Breakdown
Clinical
5
Activity
2
Company
10
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01101984 | Pre-clinical | Completed |
Competing Products
20 competing products in Dry Eye
Other Products from Santen Pharmaceutical
Eybelis ophthalmic solution 0.002%Approved
85
Aflibercept Injection [Eylea]Approved
85
STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% + STN1012600 ophthalmic solution 0.002% and Timolol ophthalmic solution 0.5%Phase 3
77
DE-117B Eye Drops + LatanoprostPhase 3
77
3% DE-089 ophthalmic solution + 0.1% sodium hyaluronate ophthalmic solutionPhase 3
77